Metabolic Syndrome and Risk of Chronic Philadelphia Negative Myeloproliferative Neoplasms (MetSaMyeloprof)
Study Overview
Status
Detailed Description
Chronic Myeloproliferative neoplasms (MPNs), such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are defined by clonal myeloid proliferation . Thrombotic events are the leading cause of morbidity and mortality in these patients . Traditional cardiovascular risk factors (CVRFs) critically exacerbate disease severity, accelerate progression to overt myelofibrosis, and significantly reduce overall survival .
Metabolic syndrome components overlap substantially with MPNs; in PV, hypertension affects 39-70%, dyslipidemia 15-38%, diabetes 7-16%, and obesity 7.5% . Epidemiological evidence demonstrates that these factors are independent predictors of arterial and venous thrombosis . while obesity is significantly linked to ET and exacerbates total symptom burden .
The mechanistic link between Metabolic syndrome and MPNs involves the JAK2V617F mutation, which induces constitutive JAK/STAT signaling and alters both lipid and glucose metabolism . MPN clones exhibit a high dependence on glucose, marked by upregulated glycolysis, elevated oxidative phosphorylation, and increased PFKFB3 expression . This metabolic reprogramming, combined with chronic systemic inflammation, cytokine overproduction, and oxidative stress, promotes severe endothelial dysfunction, accelerated atherogenesis, and hypercoagulability .
Current literature assessing different components of Metabolic syndrome in MPNs is limited by methodological gaps, often relying on retrospective data lacking comprehensive baseline metabolic parameters . Therefore, rigorous case-control designs with robust statistical extraction are required. Utilizing standard statistical software environments to perform multivariate adjustments is crucial to properly control for disease heterogeneity.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Mohammad HM AbdEllah-Alawi, Consultant
- Phone Number: +201115353591
- Email: mhmdifferent@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- chronic Philadelphia negative Myeloproliferative Neoplasms
Exclusion Criteria:
- remission
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
eligible patients already diagnosed with chronic Philadelphia negative Myeloproliferative Neoplasms
metabolic syndrome
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
relation of metabolic syndrome to clinical course chronic Philadelphia negative Myeloproliferative Neoplasms
Time Frame: 6 months
|
relation of metabolic syndrome to clinical course chronic Philadelphia negative Myeloproliferative Neoplasms
|
6 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- MetSaMyeloprof
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.